Kiniksa Pharmaceuticals International

KNSA | NASDAQ

$78.13

+$0.89 (+1.15%)

At close: Sep 21, 2026, 4:00 PM ET

$78.80

+$0.67 (+0.86%)

Pre-market: Sep 22, 2026, 7:51 AM ET

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Revenue	677.56M	423.24M	270.26M	220.18M	38.54M	n/a
Cost of Revenue	307.41M	60.91M	56.52M	22.9M	9.1M	3.81M
Gross Profit	370.15M	362.33M	213.74M	197.29M	29.44M	-3.81M
Operating Income	77.22M	-45.62M	-25.2M	9.77M	-156.64M	-157.36M
Interest Income	11.65M	9.46M	8.54M	1.25M	97K	1.13M
Pretax Income	88.87M	-36.15M	-16.65M	11.03M	-156.54M	-156.23M
Net Income	59.01M	-43.19M	14.08M	183.36M	-157.92M	-161.38M
Selling & General & Admin	196.27M	168.01M	129.43M	97.95M	85.95M	43.92M
Research & Development	96.85M	111.62M	76.1M	65.49M	99.3M	109.64M
Other Expenses	n/a	128.31M	33.41M	24.07M	835K	n/a
Operating Expenses	292.93M	407.95M	238.93M	187.51M	186.08M	153.56M
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	11.43M	n/a	n/a	n/a	n/a
Cost & Expenses	600.34M	468.86M	295.46M	210.41M	195.18M	157.36M
Income Tax Expense	29.86M	7.04M	-30.74M	-172.34M	1.39M	5.15M
Shares Outstanding (Basic)	74.2M	71.42M	70.06M	69.38M	68.58M	61.84M
Shares Outstanding (Diluted)	78.98M	71.42M	71.92M	70.42M	68.58M	61.84M
EPS (Basic)	0.80	-0.60	0.20	2.64	-2.30	-2.61
EPS (Diluted)	0.75	-0.60	0.20	2.60	-2.30	-2.61
EBITDA	90.42M	-34.46M	-14.31M	13.43M	-154.18M	-152.42M
EBIT	88.87M	-36.15M	-16.65M	11.03M	-156.54M	-156.23M
Depreciation & Amortization	1.55M	1.7M	2.34M	2.4M	2.36M	3.81M